Recombinant aav as an immune adjuvant

Abstract

The present disclosure is related to improved compositions and methods related to viral immunotherapy treatments for cancer. Specifically, provided herein are therapeutic rAAV vectors, particles, and compositions thereof related to treatment of solid tumors. Provided herein are recombinant AAV particles that express a lymphocyte-recruiting chemokine, such as CXCL9, in tumor cells, such as glial cells of the brain, and thereby modify the tumor microenvironment to sensitize the tumor to other immune therapies. Kits, pharmaceutical compositions, and methods of treatment of brain tumors and other brain malignancies are contemplated herein. Combination therapies involving the administration of any of the disclosed rAAV particles and an immune modulator are also provided.

Dependencies are inferred from the claim text.